Neuroprotective effects of punicalagin and/or micronized zeolite clinoptilolite on manganese‐induced Parkinson's disease in a rat model: Involvement of multiple pathways
Karema Abu‐Elfotuh,Ashwaq N. Abbas,Mazin A. A. Najm,Qutaiba A. Qasim,Ahmed M. E. Hamdan,Amany B. Abdelrehim,Ayah M. H. Gowifel,Aya H. Al‐Najjar,Ahmed M. Atwa,Magy R. Kozman,Azza S. Khalil,Amira M. Negm,Sara Nagdy Mahmoud Mousa,Amira M. Hamdan,Rana H. Abd El‐Rhman,Shaimaa R. Abdelmohsen,Amina M. A. Tolba,Heba Abdelnaser Aboelsoud,Ahmad Salahuddin,Alshaymaa Darwish
DOI: https://doi.org/10.1111/cns.70008
2024-10-09
CNS Neuroscience & Therapeutics
Abstract:ZC: zeolite clinoptilolite, PUN: punicalagin, PD: parkinsonism disease, Mn: manganese, ACHE: acetyl choline esterase, MDA: Malondialdehyde, SOD: Superoxide dismutase, TAC: total antioxidant capacity, DA: Dopamine, NE: norepinephrine, 5HT: serotonin, PCR: polymerase chain reaction, BAX: Bcl‐2‐associated X‐protein, Bcl2: B‐cell leukemia/lymphoma 2 protein, ELISA: Enzyme‐linked Immunosorbent Assay, Enzyme BDNF: Brain‐derived neurotrophic factor, GSK‐3β: Glycogen synthase kinase‐3 beta, glu: glutamate, PGE‐2: Prostaglandin E2, GABA: Gamma‐aminobutyric acid, CHOP: C/EBP Homologous Protein, GRP78: Glucose‐Regulated Protein 78, PERK: protein kinase‐like endoplasmic reticulum kinase, iNOS: Inducible nitric oxide synthase, IL‐1β: Interleukin ‐1β, NF‐kB: nuclear factor kappa‐light‐chain‐enhancer of activated B cells, TLR4: Toll like receptor 4, NLRP3: nucleotide‐binding domain, leucine‐rich–containing family, pyrin domain–containing‐3, COX‐2: Cyclooxygenase 2, TNF‐α: Tumor necrosis factor alpha, Nrf2: nuclear factor erythroid 2‐related factor 2, HO‐1: Heme oxygenase‐1, I.P: Intraperitoneal, P.O: oral. Background Manganism, a central nervous system dysfunction correlated with neurological deficits such as Parkinsonism, is caused by the substantial collection of manganese chloride (MnCl2) in the brain. Objectives To explore the neuroprotective effects of natural compounds, namely, micronized zeolite clinoptilolite (ZC) and punicalagin (PUN), either individually or in combination, against MnCl2‐induced Parkinson's disease (PD). Methods Fifty male albino rats were divided into 5 groups (Gps). Gp I was used as the control group, and the remaining animals received MnCl2 (Gp II–Gp V). Rats in Gps III and IV were treated with ZC and PUN, respectively. Gp V received both ZC and PUN as previously reported for the solo‐treated plants. Results ZC and/or PUN reversed the depletion of monoamines in the brain and decreased acetyl choline esterase activity, which primarily adjusted the animals' behavior and motor coordination. ZC and PUN restored the balance between glutamate/γ‐amino butyric acid content and markedly improved the brain levels of brain‐derived neurotrophic factor and nuclear factor erythroid 2‐related factor 2/heme oxygenase‐1 and decreased glycogen synthase kinase‐3 beta activity. ZC and PUN also inhibited inflammatory and oxidative markers, including nuclear factor kappa‐light‐chain‐enhancer of activated B cells, Toll‐like receptor 4, nucleotide‐binding domain, leucine‐rich‐containing family, pyrin domain‐containing‐3 and caspase‐1. Bcl‐2‐associated X‐protein and B‐cell leukemia/lymphoma 2 protein (Bcl‐2) can significantly modify caspase‐3 expression. ZC and/or PUN ameliorated PD in rats by decreasing the levels of endoplasmic reticulum (ER) stress markers (p‐protein kinase‐like ER kinase (PERK), glucose‐regulated protein 78, and C/EBP homologous protein (CHOP)) and enhancing the levels of an autophagy marker (Beclin‐1). Discussion and Conclusion ZC and/or PUN mitigated the progression of PD through their potential neurotrophic, neurogenic, anti‐inflammatory, antioxidant, and anti‐apoptotic activities and by controlling ER stress through modulation of the PERK/CHOP/Bcl‐2 pathway.
pharmacology & pharmacy,neurosciences